// App-Quantinova.ai

SAT0102 : NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB

Researchers

Presenter

  • E. Choy

Principal Investigators

  • V. Bykerk

  • Y. Lee

  • G. St John

  • H. Van Hoogstraten

  • K. Ford

  • A. Praestgaard

  • A. Sebba

Medical Centers

  • Cardiff University, Cardiff, United Kingdom

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Northwestern University, Chicago, United States of America

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Sanofi US, Bridgewater, United States of America

  • Sanofi Genzyme, Cambridge, MA, United States

  • University of South Florida, Tampa, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Sarilumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01061736

  • NCT02332590

  • NCT01709578

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved